Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?

References

• Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980;4:547–559.
   PubMed Web of Science ®Google Scholar
• Dunphy CH, Petruska PJ. Atypical prolymphocytic variant of hairy-cell leukemia: case report and review of the literature. Am J Hematol. 1996;53:121–125.
   PubMed Web of Science ®Google Scholar
• Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003;16:41–56.
   PubMed Web of Science ®Google Scholar
• Sainati L, Matutes E, Mulligan S, et al. A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood. 1990;76:157–162.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Lauria F, Buzzi M, et al. Hairy cell leukemia variant: a morphologic, immunologic and clinical study of 7 cases. Haematologica. 1990;75:54–57.
   PubMed Web of Science ®Google Scholar
• Matutes E, Wotherspoon A, Brito-Babapulle V, et al. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia. 2001;15:184–186.
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Matutes E, Morilla R, et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica. 2004;89:303–308.
   PubMed Web of Science ®Google Scholar
• Hockley SL, Morgan GJ, Leone PE, et al. High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia. Leukemia. 2011;25:1189–1192.
   PubMed Web of Science ®Google Scholar
• Hockley SL, Giannouli S, Morilla A, et al. Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol. 2010;148:666–669.
   PubMed Web of Science ®Google Scholar
• Arons E, Suntum T, Stetler-Stevenson M, et al. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114:4687–4695.
   PubMed Web of Science ®Google Scholar
• Angelova EA, Medeiros LJ, Wang W, et al. Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. J Mod Pathol. 2018;31(11):1717–1732.
   PubMed Web of Science ®Google Scholar
• Maitre E, Bertrand P, Maingonnat C, et al. New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. Oncotarget. 2018;9(48):28866–28876.
   PubMedGoogle Scholar
• Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119:3330–3332.
   PubMed Web of Science ®Google Scholar
• Waterfall JJ, Arons E, Walker RL, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46:8–10.
   PubMed Web of Science ®Google Scholar
• Piris A, Foucar K, Mollejo M, et al. Splenic B-cell lymphoma/leukaemia unclassifiable. In: Swerdlow SH, Campo E, Jaffe ES, et al.editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017. p. 229–231.
   Google Scholar
• Matutes E, Martínez-Trillos A, Campo E. Hairy cell leukaemia-variant: disease features and treatment. Best Pract Res Clin Haematol. 2015;28(4):253–263.
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. US lymphoid malignancy statistics by World Health Organization subtypes. Cancer J Clin. 2016;66(6):443–459.
   PubMed Web of Science ®Google Scholar
• Robak T, Matutes E, Catovsky D, et al.; Buske C ESMO Guidelines Committee. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015;26:v100–7.
   PubMed Web of Science ®Google Scholar
• Pillai V, Pozdnyakova O, Charest K, et al. CD200 flow cytometric assessment and semiquantitative immunohistochemical staining distinguishes hairy cell leukemia from hairy cell leukemia-variant and other B-cell lymphoproliferative disorders. Am J Clin Pathol. 2013;140:536–543.
   PubMed Web of Science ®Google Scholar
• Van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–1975.
   PubMed Web of Science ®Google Scholar
• Baseggio L, Traverse-Glehen A, Callet-Bauchu E, et al. Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL). Hematol Oncol. 2011;29(1):47–51.
   PubMed Web of Science ®Google Scholar
• Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood. 2009;114:4696–4702.
   PubMed Web of Science ®Google Scholar
• Martinez D, Navarro A, Martinez-Trillos A, et al. NOTCH1, TP53 and MAP2K1 mutations in splenic diffuse red pulp small B-cell lymphoma are associated with progressive disease. Am J Surg Pathol. 2016;40(2):192–201.
   PubMed Web of Science ®Google Scholar
• Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood. 2008;111:2253–2260.
   PubMed Web of Science ®Google Scholar
• Kanellis G, Mollejo M, Montes-Moreno S, et al. Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica. 2010;95:1122–1129.
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307–5316.
   PubMed Web of Science ®Google Scholar
• Bikos V, Darzentas N, Hadzidimitriou A, et al. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia. 2012;26:1638–1646.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–2315.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Pettirossi V, Schiavoni G. Falini B genomics of hairy cell leukemia. J Clin Oncol. 2017;35(9):1002–1010.
   PubMed Web of Science ®Google Scholar
• Dietrich S, Hüllein J, Lee SC, et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. 2015;126(8):1005–1008.
   PubMed Web of Science ®Google Scholar
• Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124:1655–1658.
   PubMed Web of Science ®Google Scholar
• Wu JN, Roberts CWM. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013;3:35–43.
   PubMed Web of Science ®Google Scholar
• Hahn CN, Scott HS. Spliceosome mutations in hematopoietic malignancies. Nat Genet. 2012;44:9–10.
   Web of Science ®Google Scholar
• Mason EF, Brown RD, Szeto DP, et al. Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leuk Lymphoma. 2017;58(1):233–236.
   PubMed Web of Science ®Google Scholar
• Hockley SL, Else M, Morilla A, et al. The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol. 2012;158:347–354.
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Martínez-Trillos A, et al.,Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. Haematologica. 2017;102(9):e360–e363.
   PubMed Web of Science ®Google Scholar
• Flatley E, Chen AI, Zhao X, et al. Aberrations of MYC are a common event in B-cell prolymphocytic leukemia. Am J Clin Pathol. 2014;142:347–354.
   PubMed Web of Science ®Google Scholar
• the Groupe Francophone de Cytogénétique Hématologique (GFCH); the French Innovative Leukemia Organization (FILO); Chapiro E, Pramil E, Diop M, et al. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. Blood. 2019;134(21):1821–1831.
   PubMed Web of Science ®Google Scholar
• Zanelli M, Ragazzi M, Riccardo Valli R, et al. Transformation of IGHV4‐34+ hairy cell leukaemia‐variant with U2AF1 mutation into a clonally‐related high grade B‐cell lymphoma responding to immunochemotherapy. Br J Haematol. 2016;173:480–495.
   PubMed Web of Science ®Google Scholar
• Matutes E. Novel and emerging drugs for rarer chronic lymphoid leukaemias. Curr Cancer Drug Targets. 2012;12:484–504.
   PubMed Web of Science ®Google Scholar
• Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev. 2006;32:365–376.
   PubMed Web of Science ®Google Scholar
• Makita M, Nakamura K, Kono A. Successful rituximab treatment in a patient with refractory hairy cell leukemia-Japanese variant and suffering from acute respiratory distress. Rinsho Ketsueki. 2005;46:1196–1201.
   PubMedGoogle Scholar
• Narat S, Gandla J, Dogan A, et al. Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma. 2005;46:1229–1232.
   PubMed Web of Science ®Google Scholar
• Quach H, Januszewicz H, Westerman D. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica. 2005;90:ECR26.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Mihara K, Sugihara S, et al. Splenectomy followed by administration of rituximab is useful to treat a patient with hairy cell leukemia-variant. Ann Hematol. 2013;92:711–713.
   PubMed Web of Science ®Google Scholar
• Quigley MM, Bethel KJ, Sharpe RW, et al. CD52 expression in hairy cell leukemia. Am J Hematol. 2003;74:227–230.
   PubMed Web of Science ®Google Scholar
• Telek B, Batár P, Udvardy M. Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant. Orv Hetil. 2007;148:1805–1807.
   PubMedGoogle Scholar
• Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241–247.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30:1822–1828.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768–1777.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011;118:3818–3823.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson W, Calvo KR, et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res. 2013;19:6873–6881.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Arons E. Update on hairy cell leukemia. Clin Adv Hematol Oncol. 2018;16(3):205–215.
   PubMed Web of Science ®Google Scholar
• Letendre P, Doll D. Novel therapeutics in the treatment of hairy cell leukemia variant. Leuk Res. 2018;75:58–60.
   PubMed Web of Science ®Google Scholar
• Visentin A, Imbergamo S, Frezzato F, et al. Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. Oncotarget. 2017;8(66):110727–110731.
   PubMedGoogle Scholar
• Wiber M, Maitre E, Cornet E, et al. Variant form of hairy cell leukemia. Clin Case Rep. 2019;7(6):1161–1166.
   PubMed Web of Science ®Google Scholar
• Visentin A, Imbergamo S, Trimarco V, et al. Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature. Hematol Oncol. 2020;38(5):823–826.
   PubMed Web of Science ®Google Scholar